Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
2 hedge funds and large institutions have $7.82K invested in Achilles Therapeutics in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 4 closing their positions.
67% less funds holding
Funds holding: 6 → 2 (-4)
90% less capital invested
Capital invested by funds: $80.2K → $7.82K (-$72.4K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$57.6K |
| 2 |
BAM
Brave Asset Management
Summit,
New Jersey
|
-$14.5K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
-$290 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
RhumbLine Advisers
Boston,
Massachusetts
| $6.63K | – | – | – |
|
|
GI
2
GAMMA Investing
Foster City,
California
| $1.19K | – | – | – |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| – | -$57.6K | -38,923 | Closed |
|
|
BAM
4
Brave Asset Management
Summit,
New Jersey
| – | -$14.5K | -10,000 | Closed |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| – | -$290 | -196 | Closed |
|
ACHL Hedge Fund Activity: Q2 2025 in Review
2 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q2 2025, worth a combined $7.82K — down 90% from $80.2K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ACHL and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was XTX Topco, exiting entirely with an estimated $57.6K sold.
- 2 institutional investors held Achilles Therapeutics (ACHL) as of Q2 2025, down from 6 in Q1 2025.
- Funds reported $7.82K of Achilles Therapeutics stock for Q2 2025, down 90% quarter-over-quarter.
- 0 funds opened new Achilles Therapeutics positions in Q2 2025 and 4 closed out, a net change of -4 holders.
- The largest Achilles Therapeutics seller in Q2 2025 was XTX Topco, an estimated $57.6K sold.
Based on aggregated 13F filings for Q2 2025.